Cilcare appoints Dr. Preethi Sundaram to its Board of Directors

Preethi Sundaram

Montpellier, January 30, 2025 – Cilcare, a biotechnology company specializing in auditory sciences, is pleased to announce the appointment of Dr. Preethi Sundaram to its Board of Directors. With 25 years of experience in the pharmaceutical industry, Dr. Sundaram brings exceptional expertise in drug development, commercialization, and business development strategies, including mergers and acquisitions. She joins Cilcare at a strategic juncture to contribute to the company’s mission of leveraging precision auditory sciences to redefine and reimagine the future of care for patients with hearing disorders.

We are thrilled to welcome Dr. Sundaram to our Board of Directors. Her recognized expertise in the pharmaceutical industry and strong leadership qualities perfectly align with our long-term growth strategy. We are confident that her contributions will be instrumental in achieving our goal of advancing early detection and precision treatment of hearing disorders” said Celia Belline, CEO of Cilcare.

Dr. Sundaram also expressed her enthusiasm for joining the company:

It is an honor to join Cilcare at such a pivotal time in its journey. The company has shown remarkable progress in recent years and is ideally positioned to leverage its established expertise and capabilities to become a key player in hearing care, serving patients worldwide. I look forward to collaborating with the Board and executive team to support the implementation of the company’s strategic growth plans.”

Dr. Preethi Sundaram joined Cilcare’s Board of Directors on December 2, 2024. Over the course of her 25-year career in the pharmaceutical industry, she has overseen the development and launch of several essential medical treatments. Since 2021, she has served as Chief Strategy Officer at Catalyst Pharmaceuticals, where she leads the company’s growth strategy with a focus on business development, new product acquisitions, portfolio expansion, and product lifecycle management.

Prior to joining Catalyst, Dr. Sundaram held leadership positions at Sanofi starting in 2005, across various therapeutic areas and business units. She served in various leadership roles, including Global Clinical Research Director, Global Project Head, and Global Head, Medical Operations for the General Medicines business unit. She also held positions at Abbott Laboratories, Covance, and Neurovision prior to her tenure at Sanofi.

Dr. Sundaram holds several prestigious degrees, including a Bachelor of Science in Optometry from the Elite School of Optometry & BITS (India), a Bachelor of Arts in Psychology from the University of Madras (India), a Doctorate in Optometry from Anglia Ruskin University (UK), and an Executive Business Master’s from the London Business School.

With this appointment, Cilcare strengthens its commitment to transforming hearing care and improving the quality of life for patients with hearing disorders.

Press contact Marie Peytavy, Marketing & Communication Director: marie.peytavy@cilcare.com

About Cilcare

Cilcare is a biotechnology company specializing in auditory sciences, developing cutting-edge solutions for the characterization, diagnosis, and treatment of hearing disorders and associated diseases. Founded by three visionary entrepreneurs, the company now employs a team of 45 international collaborators, supported by a scientific advisory board. Since its creation in 2014, Cilcare has dedicated itself to addressing these global challenges by combining an advanced R&D platform, a promising drug candidate portfolio, and the use of artificial intelligence and machine learning to characterize various forms of hearing loss.

For the past 10 years, Cilcare has also made its technology available to industry leaders and researchers in Europe, the United States, and Asia to accelerate the development of drugs, gene and cell therapies, and medical devices for hearing disorders.

Link to Press Release (French Version)

Link to Press Release (English version)

Share the Post: